Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers

Hormones and Cancer

Volumn 5, Issue 6, 2014, Pages 405-413

  Sieuwerts, Anieta M ^a   Willis, Scooter ^d   Burns, Michael B ^b   Look, Maxime P ^a   Gelder, Marion E Meijer Van ^a   Schlicker, Andreas ^c   Heideman, Marinus R ^c   Jacobs, Heinz ^c   Wessels, Lodewyk ^c   Leyland Jones, Brian ^d   Gray, Kathryn P ^e   Foekens, John A ^a   Harris, Reuben S ^b   Martens, John W M ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d Avera Health   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; ESTROGEN RECEPTOR; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; BREAST NEOPLASMS; CANCER STAGING; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL; UPREGULATION;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COHORT STUDIES; CYTIDINE DEAMINASE; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RNA, MESSENGER; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 84939881660     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-014-0196-8     Document Type: Article

References (40)

1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR et al (2013) Signatures of mutational processes in human cancer. Nature 500(7463):415–421
2. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW et al (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494(7437):366–370
3. Burns MB, Temiz NA, Harris RS (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45(9):977–983
4. Cancer Genome Atlas, Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70
5. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45(10):1127–1133
6. Conticello SG (2008) The AID/APOBEC family of nucleic acid mutators. Genome Biol 9(6):229
7. Conticello SG (2012) Creative deaminases, self-inflicted damage, and genome evolution. Ann N Y Acad Sci 1267:79–85
8. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352
9. Di Noia JM, Neuberger MS (2007) Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 76:1–22
10. Etard C, Roostalu U, Strahle U (2010) Lack of Apobec2-related proteins causes a dystrophic muscle phenotype in zebrafish embryos. J Cell Biol 189(3):527–539
11. Gotoh T, Aoyama K (1990) The method of total heminephroureterectomy–application of mucolysis. Nihon Hinyokika Gakkai Zasshi 81(1):14–18
12. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446(7132):153–158
13. Gyorffy B, Lanczky A, Szallasi Z (2012) Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 19(2):197–208
14. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
15. Komatsu A, Nagasaki K, Fujimori M, Amano J, Miki Y (2008) Identification of novel deletion polymorphisms in breast cancer. Int J Oncol 33(2):261–270
16. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, Emerman M, Greene WC et al (2009) Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 83(2):494–497
17. Li M, Shandilya SM, Carpenter MA, Rathore A, Brown WL, Perkins AL, Harki DA et al (2012) First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol 7(3):506–517
18. Long J, Delahanty RJ, Li G, Gao YT, Lu W, Cai Q, Xiang YB et al (2013) A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst 105(8):573–579
19. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, N. C. I. EORTC Working Group on Cancer Diagnostics Statistics (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16)):1180–1184
20. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D et al (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149(5):979–993
21. Olson ME, Li M, Harris RS, Harki DA (2013) Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. ChemMedChem 8(1):112–117
22. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752
23. Prlic A, Yates A, Bliven SE, Rose PW, Jacobsen J, Troshin PV, Chapman M et al (2012) BioJava: an open-source framework for bioinformatics in 2012. Bioinformatics 28(20):2693–2695
24. Refsland EW, Harris RS (2013) The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol 371:1–27
25. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38(13):4274–4284
26. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12(12):1101–1108
27. Robbiani DF, Nussenzweig MC (2013) Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. Annu Rev Pathol 8:79–103
28. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A et al (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45(9):970–976
29. Sato Y, Probst HC, Tatsumi R, Ikeuchi Y, Neuberger MS, Rada C (2010) Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy. J Biol Chem 285(10):7111–7118
30. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, Kobayashi M, Kadowaki N, Takaori-Kondo A (2012) APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep 2:806
31. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA (2005) How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 11(20):7311–7321
32. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, Timmermans M, Martens JW, Brunner N, Klijn JG, Offenberg H, Foekens JA (2007) Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem 53(7):1280–1288
33. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, Bignell G et al (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37(6):590–592
34. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA et al (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276):1005–1010
35. Strebel K, Luban J, Jeang KT (2009) Human cellular restriction factors that target HIV-1 replication. BMC Med 7:48
36. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS (2013) DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2:e00534
37. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009
38. Vonica A, Rosa A, Arduini BL, Brivanlou AH (2011) APOBEC2, a selective inhibitor of TGFbeta signaling, regulates left-right axis specification during early embryogenesis. Dev Biol 350(1):13–23
39. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679
40. Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, Shu XO, Kelley MC, Zheng W, Long J (2013) APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis 34(10):2240–2243